To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-
infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical …

Purpose To evaluate long-term efficacy and safety of extended treatment with adalimumab
in patients with noninfectious intermediate, posterior, or panuveitis. Design Open-label …

The aim of the present study was to compare long-term adalimumab (ADA) and infliximab
(IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims …

Objective The aim of this study was to assess the efficacy of adalimumab in patients with
active non-infectious uveitis in three different centres. Methods In a retrospective study we …

OBJECTIVE: To evaluate adalimumab therapy in refractory uveitis. DESIGN: Prospective
case series. PARTICIPANTS: A total of 131 patients with refractory uveitis and intolerance or …

Purpose To evaluate safety and efficacy of adalimumab in patients with noninfectious
intermediate, posterior, or panuveitis. Design Phase 3, open-label, multicenter clinical trial …

Purpose: The aim of this study was to assess the efficacy and safety of adalimumab in
treating refractory autoimmune uveitis. Methods: This work was a prospective …

Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐
TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab …

Importance Adalimumab was recently approved for the treatment of noninfectious
intermediate uveitis, posterior uveitis, and panuveitis. Objective To assess the effect of …

Purpose: To describe the corticosteroid-sparing success in controlling chronic uveitis in
patients treated with TNFα inhibitors. Methods: Retrospective longitudinal case series of …